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Abstract Influenza A virus causes prevalent respiratory
tract infections in humans. Small interfering RNA (siRNA)
and antisense oligonucleotides (asODNs) have been used
previously for silencing the RNA genome of influenza
virus. Here, we explored the use of partially double-
stranded oligodeoxynucleotides (dsODNs) to suppress the
production of influenza A virus in cell cultures and animal
models. We were able to inhibit influenza A virus repli-
cation in cultured human lung cells as well as in the lungs
of infected C57BL/6 mice by treatment with dsODN 3-h
post-infection. In about 20% of the cases (15/77) the titer
was reduced by 10- to 100-fold and in 10% up to 1,000-
fold. The antiviral effects of dsODNs were dose-dependent,
sequence-dependent and comparable to those of its anti-
sense and siRNA analogues. Thus, dsODNs may be
developed as an additional class of nucleic acids for the
inhibition of influenza virus replication.
Many RNA viruses and retroviruses, such as influenza A
virus, Ebola virus and HIV, are highly infectious agents
which cause severe diseases in humans. The RNA genomes
of these viruses have been important targets of nucleic-
acid-based gene silencing agents such as antisense oligo-
nucleotides and small interfering RNA [1]. We have
recently applied a different group of oligonucleotides,
referred to as partially double-stranded, hairpin-loop-
structured oligodeoxynucleotides, to target HIV-1 RNA
[2–6] as well as the RNA of spleen focus-forming virus in a
mouse leukemia model [7]. The antisense strand of the
dsODN is complementary to the 30 polypurine tract (PPT)
of the retrovirus; it forms a DNA/RNA hybrid with the
retroviral RNA, which then activates the retroviral reverse
transcriptase/ribonuclease H (RT/RNase H) to cleave at the
PPT 50 to the ACU sequence, triggering a premature deg-
radation of the viral RNA and hence abrogation of viral
replication [8]. Here, we investigated the ability of
dsODNs to induce the degradation of influenza RNA and
hence the abrogation of influenza A production in cultured
human lung cells and mouse lung.
Influenza A virus, a member of the family Orthomyxo-
viridae, possesses eight RNA genome segments (PB1, PB2,
PA, NP, HA, M, NS and NA), which are coated by the
nucleoprotein NP [9]. During influenza replication, the
virion RNA (vRNA, - strand) is transcribed into mRNA
(? strand) and complementary RNA (cRNA, ? strand),
which serve as templates for the synthesis of viral proteins
and new vRNA, respectively. Influenza virus RNA
polymerase plays an essential role in viral replication. Its
activities include binding of capped RNA, endonuclease
cleavage, and RNA-directed RNA transcription activity.
Furthermore, the RNA polymerase of influenza virus is
highly conserved among influenza viruses A, B, and C [10].
Thus, influenza virus RNA polymerase is a promising target
for inhibition of viral replication. Influenza virus RNA
polymerase consists of three subunits, PB1, PB2 and PA. The
dsODNs analyzed in this study target the mRNA and cRNA
of the PA gene (Fig. 1a). The dsODNs contain three thioated
nucleotides at either end and four in the thymidine T4 linker.
ODN A, a dsODN that targets the PPT region of the HIV-1
genomic RNA, served as control (Fig. 1a) [2–6]. The vertical
bars indicate Watson–Crick bonds, indicating that the ODNs
are hairpin-looped structures.
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We first examined the effects of dsDNA PA50 (Fig. 1a)
on influenza virus replication in MDCK cells, Vero cells
(data not shown) and the human lung cell line A549 [11].
The cells were pre-treated with either dsODN PA50, siRNA
PA50, asDNA PA50 or ODN A (Fig. 1a) as negative control
in the presence of Lipofectamine 2000 (Invitrogen). After
5 h, the cells were infected with influenza A/PR/8/34 at a
multiplicity of infection (MOI) of 0.2. The calcium channel
blocker Verapamil (Biomol), recently shown to exert a
strong anti-influenza A virus activity [12], was added to the
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Fig. 1 a The oligonucleotides used in this study. The target sequences
of the two regions, PA50 and PAsi, of the PA gene in the influenza
mRNA and cRNA are shown in bold. PAsi was selected previously for
siRNA targeting by PA-2087 [13]. The Watson–Crick bonds are
represented by vertical bars. In dsDNA PA50M, the 20-O-methylated
bases are underlined. In dsDNA PA50L, the locked-nucleic-acid
(LNA)-modified bases are overlined. ODN A targets HIV-1 genomic
RNA and served as a control. Capital letters indicate deoxyribonu-
cleotides, lower-case letters ribonucleotides. All ODNs had three
thioate-modified nucleotides at either end and four within the
thymidine T4 linker. b Short double-stranded DNA (dsDNA PA50)
targeting the PA gene specifically inhibited replication of influenza A
virus in vitro. The time of transfection of the ODNs is indicated by an
arrowhead. Infection is defined as time point 0 h and indicated by a
thick arrow on the time line. Thin arrows indicate the times at which
the supernatants were collected and the virus titer was determined. The
A549 lung cells were grown to 90% confluency and transfected with
the various oligonucleotide-Lipofectamine 2000 complexes (80 pmol
nucleic acid and 3.3 or 4 ll Lipofectamine 2000 for DNA or RNA,
respectively) 5 h prior to infection. Untreated controls received only
medium. The cells were washed twice with phosphate-buffered saline
(PBS) before infection with influenza virus A/PR/8/34 at MOI 0.2.
Two-hour post-infection, Verapamil, a previously described inhibitor
of influenza virus [12] was added to the medium at a non-toxic
concentration (100 lM). Sixteen hours after infection, supernatants
were collected for RNA isolation, as indicated by a thin arrow.
Relative amounts of influenza viral RNA were determined by real-time
reverse transcriptase polymerase chain reaction (RT-PCR) using
primers and probes specific for the NP gene; n = 6. Data are expressed
as mean ? SE of the mean (SEM). Statistical significance was
determined using the Student’s unpaired two-tailed t-test. A probabil-
ity of P B 0.05 is considered significant and is indicated with an
asterisk. Double asterisks denote P B 0.01. c In vitro kinetics of
influenza A replication in cells treated with dsDNA. The sequence of
events is summarized by the time line, as described in Fig. 1b. A549
cells were grown to 70% confluency. The cells were transfected with
complexes of 8 ll Lullaby and 80 pmol oligonucleotides. Six hours
after transfection, the cells were washed twice with PBS and infected
with influenza virus A/PR/8/34 at MOI 0.01. Supernatant was
collected at 16-, 24- and 40-h post-infection for the quantitation of
influenza RNA; n = 6. Data are expressed as mean ? SEM. Statis-
tical significance was determined as described in Fig. 1b
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medium 2-h post-infection at a non-toxic concentration
(100 lM) and served as positive control. At 16-h post-
infection, viral RNA was isolated from the culture super-
natant, reverse transcribed into cDNA using random
primers and then quantified by real-time polymerase chain
reaction (PCR) using primers and probes specific for NP
cDNA. Statistical analysis was carried out using either the
Student’s t-test or analysis of variance with the Bonferroni
post hoc test. Statistical significance is indicated by one
asterisk (P B 0.05) or two asterisks (P B 0.01). In com-
parison to the untreated or ODN A-treated controls, pre-
treatment of A549 cells with dsDNA PA50 resulted in a
significant 54% (P = 0.005) and 40% (P = 0.014) inhi-
bition of virus growth (Fig. 1b). We did not observe any
Fig. 2 dsDNAs inhibited the replication of influenza A virus in
mouse lungs. The time lines show time of infection at 0 h (thick
arrow), time points of treatment (arrowheads) and lung harvesting for
PCR analysis (thin arrows). Simultaneous events are overlined.
a Simultaneous therapy. The oligonucleotide-Lipofectamine 2000
complex (2.5 ll Lipofectamine 2000 and 1 lg nucleic acid) was
mixed with 200 TCID50 of influenza virus A/PR/8/34. The resultant
mixture (20 ll) was applied intranasally. The untreated control
consisted of a PBS-virus mixture. Lungs were harvested 24 h after
infection for the extraction of total RNA and PCR analysis. Groups of
five mice (n = 5) were analyzed. Relative amounts of influenza RNA
were determined as described in Fig. 1b. b Single-dose therapy at 2-h
post-infection. A dose of 200 TCID50 of influenza virus A/PR/8/34 in
20 ll was administered intranasally. Two hours after infection, the
oligonucleotide-Lipofectamine 2000 complex (20 ll) was adminis-
tered intranasally. Lungs were harvested 24 h after infection for
quantitation of influenza RNA; n = 5–10 per group. The data shown
are combined from two different experiments. Statistical analysis of
the data was performed by determining the variance with the
Bonferroni post hoc test applied to logarithmically transformed data
using SPSS 16.0 (SPSS Inc. IL). Statistical significance is indicated
by a single asterisk (P B 0.05) and a double asterisk (P B 0.01).
c Double-dose therapy. Suppression of influenza virus replication
with dsDNA PA50 is shown in comparison to PBS (untreated) control.
A mixture (40 ll) of 300 TCID50 of influenza virus A/PR/8/34 and
oligonucleotide-lipofectamine complex was administered intranasally
as described in a. Three hours after infection, a second dose of
oligonucleotide-lipofectamine complex (20 ll) was administered
intranasally. Mouse lungs were harvested 24 h after infection for
the quantitation of influenza virus RNA. The data shown are
combined from three different experiments. n = 15–40 per group.
Viral RNA copies were determined for left and right lungs
individually (represented by individual dots). Statistical significance
is indicated by an asterisk (P B 0.05) and was determined as
described in Fig. 1b. Data are expressed as mean ? SEM in bar
charts on a linear scale (left) and individual dots with median
(numerical middle value of a group of data points) on a logarithmic
scale (right). d Top Mean and median values were calculated from the
titers in copies per assay (cpa). The -fold decrease is the ratio of titers
of untreated versus treated mice. d Bottom Based on the mean value
of 1010 cpa in the untreated group, mice of the treated group were
categorized by viral load. Groups are expressed as -fold reduction.
A -fold decrease smaller than 1 indicates an increase
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significant reduction of virus growth by siRNA PA50 or
asDNA PA50 (Fig. 1b). To compare the effect under dif-
ferent transfection conditions, Lipofectamine 2000 was
replaced with another transfection reagent, Lullaby (Oz
Biosciences). A similar inhibition of virus growth was
observed with dsDNA PA50 compared to ODN A at 16 h
(50%, P = 0.001), 24 h (77%, P = 0.004), and 40-h post-
infection (81%, P = 0.014) (Fig. 1c). Although treatment
with Lullaby and ODN A led to reduced viral RNA levels
compared to untreated samples, the fact that these inhibi-
tory effects were consistently weaker than those observed
with dsDNA PA50 (Fig. 1c) suggests that the inhibition by
dsDNA PA50 was sequence-dependent. The significant
inhibitory effect observed with the ODN A-Lullaby com-
plex suggests the possibility of an off-target effect. To
assess toxicity, dsDNAPA50 and asDNAPA50 were tested
at tenfold higher amounts (800 pmol) in the absence of any
transfection agents. No cytopathic effect was observed.
Moreover, application of either compound (80 pmol) to
human A549 cells in the presence of a transfection agent
did not induce a detectable interferon type I response as
tested by immunofluorescence analysis of the interferon-
inducible MxA protein (data not shown).
Next, we analyzed the in vivo efficacy of dsDNA PA50 in
influenza-virus-infected C57BL/6 mice. Intranasal admin-
istration of dsDNA PA50 resulted in a 40–98% reduction of
influenza virus production in the mouse lungs, depending on
the therapeutic regimen used (Fig. 2a–c). Simultaneous
administration of dsDNA PA50 and virus resulted in a ten-
fold reduction of viral RNA in the lungs (Fig. 2a), while a
single treatment with dsDNA PA50 2-h post-infection
reduced viral RNA more than 97% (P = 8.4 9 10-5)
(Fig. 2b). Interestingly, the double therapy in which the
dsDNA PA50-Lipofectamine 2000 complex was adminis-
tered both simultaneously with influenza A virus and at 3-h
post-infection, did not result in a further increase of the
antiviral effect compared to a single treatment at either 0- or
2-h post-infection. Ge and co-workers reported previously
that the siRNA PA-2087, which targets the 30 region of the
PA mRNA, resulted in a more than 15-fold inhibition of
influenza virus A/PR/8/34 and A/WSN/33 replication in
Madin–Darby canine kidney (MDCK) cells and a roughly
tenfold inhibition in the lungs of C57BL/6 mice [13, 14].
We hence tested the inhibitory effect of dsDNA PAsi,
which targets the same region of PA mRNA as PA-2087.
dsDNA PAsi was capable of a slight inhibition in the
simultaneous treatment (Fig. 2a) and a stronger inhibition
of influenza virus replication when administered at 2-h post-
infection (Fig. 2b). As evidenced in Fig. 1b and c, treatment
with HIV-1-specific ODN A control clearly lead to the
reduction of influenza A virus titer by an unknown, target-
sequence-independent mechanism. As mentioned previ-
ously [7, 15], ODN A can form high-molecular-weight
structures, possibly G-tetrads. However, very recent
observations show that dsDNA PA50 exists only in the
monomeric form (Heinrich and Moelling, unpublished
data). The sequence-independent inhibitory effect of ODN
A against influenza A virus may be explained by its olig-
omeric structures, making it a poor negative control. For
this reason we have omitted ODN A treatment as negative
control in the animal experiments shown in Figs. 2 and 3.
Using larger numbers of animals per group (n = 15–
40), it was confirmed that the inhibitory effect of dsDNA
PA50 was significant when compared to an untreated con-
trol (P = 0.043) (Fig. 2c). The reduction of the average
titer was twofold and that of the median fourfold (Fig. 2c,
d). A high variability is observed, which may be attribut-
able to the nasal treatment of the mice, which is not easily
controlled and required a large number of animals. More-
over, 20% (15/77) of the dsDNA PA50-treated lungs
showed a 10-to-100-fold reduction of viral RNA, and 10%
(9/77) of the treated mice exhibited a reduced viral titer in
the lungs up to 1,000-fold. A few mice (3/77) even showed
a reduction of 1,000- to 10,000-fold (Fig. 2d). None of the
ODNs administered to the mice described in Figs. 2 and 3
led to an overt increase of the size of liver or spleen, even
when 1 lg of ODN was used, indicating low toxicity. Our
results show that dsDNA PA50 exerted a more effective
inhibition when the tissue culture infectious dose 50
(TCID50) was 200 compared to TCID50 of 300 or 400
(equals 280 plaque-forming units), indicating that the
efficacy of dsDNA PA50 depended on the input viral dose
(Fig. 3a). In addition, dsDNA PA50 inhibited influenza
virus production in the lungs in a dose-dependent manner
(Fig. 3b). Finally, we investigated whether chemical
modifications such as 20-O-methylation (M) or locked-
nucleic-acid (LNA) chemistry might be able to further
enhance the antiviral effect of dsDNA PA50 (designated
dsDNA PA50 M, or dsDNA PA50 L, respectively, shown in
Fig. 1a). Analysis of the viral titers in the lung indicated
that modification of dsDNA PA50 by 20-O-methylation
improved the in vivo efficacy of dsDNA PA50 by 75%
(P = 0.019) (Fig. 3c). In the case of LNA modifications,
we did not observe an improvement (data not shown);
however, to determine the location and number of modified
nucleotides, a more systematic analysis is required.
In summary, we have shown here that a dsDNA
designed to target the 50 end of the mRNA of the influenza
virus RNA polymerase was able to inhibit influenza virus
replication in cell culture as well as in mouse lungs. The
observed antiviral effects of dsDNA PA50 were slightly
superior to those of asDNA PA50 and siRNA PA50 in the
A549 human lung cell line and in lungs of C57BL/6 mice.
The anti-influenza virus activity of dsDNAPA50 appears to
be primarily sequence-dependent. The higher efficacy of
dsODNs compared to single-stranded asDNA or siRNA
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may be due to more favorable in vivo pharmacokinetics
and protection against nucleases by the hairpin-loop stuc-
ture. Ge and co-workers reported previously that intranasal
administration of 60 lg of siRNA PA-2087, which targets
the 30 region of the PA mRNA, resulted in an approxi-
mately tenfold inhibition in the lungs of C57BL/6 mice
[13, 14]. In this study, dsDNA PAsi, the dsDNA variant of
PA-2087, exhibited a similar potency at a dose as low as
1 lg per animal. Interestingly, when administered simul-
taneously with infection, the efficacy of dsDNA PAsi was
lower than that of dsDNA PA50, suggesting that the anti-
viral effects of dsDNA, like those of siRNA or asODNs,
could be determined by the structure and accessibility of
the target mRNA. We noticed a faster response of the mice
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Fig. 3 The effects of viral dose, oligonucleotide dose, and nucleotide
sequence in mice. Mice were infected intranasally as described in
Fig. 2. ODN (1 lg) was used per treatment unless otherwise stated.
The lungs were harvested 24 h after infection for the quantitation of
influenza virus RNA. a Effects of viral dose. C57BL/6 mice were
infected intranasally with 200 (20 ll), 300 (40 ll) or 400 (40 ll)
TCID50 of influenza virus A/PR/8/34 and were treated at 0 h and at
2- or 3-h post-infection with dsDNA PA50 or PBS (untreated control)
as shown in the time line; n = 5–15 per group. Statistical significance
is indicated by a double asterisk (P B 0.01) and was determined as
described in Fig. 2b. b Dose dependence of dsDNA PA50. C57BL/6
mice were infected intranasally with 200 or 400 TCID50 of influenza
virus A/PR/8/34 and were treated twice with 0.1, 0.3 or 1 lg (per
treatment) of dsDNA PA50 or PBS (untreated control) as shown in the
time line. The data shown are combined from two different
experiments. n = 5–10 per group. c 20-O-methyl modification (M)
of dsDNA PA50 (see Fig. 1a). C57BL/6 mice were infected intrana-
sally with 400 TCID50 (40 ll) of influenza virus A/PR/8/34 and were
treated at 2-h post-infection with 1 lg of dsDNA PA50 or dsDNA
PA50M complexed with Lipofectamine 2000. The lungs were
harvested 24 h after infection for the quantitation of influenza virus
RNA; n = 5 per group. Statistical significance is indicated by an
asterisk (P B 0.05) and was determined as described in b. The data
are shown as mean ? SEM
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to dsODN than to siRNA by several hours, which may be
explained by the different mechanisms. The dsODN does
not require an unwinding step in a RISC particle, and the
formation of an RNA/DNA hybrid is thermodynamically
more favorable than double-stranded RNA.
In the case of an influenza virus infection it is essential
to immediately inhibit viral replication. We demonstrate
here that application of dsODN, even 3-h post-infection,
reduces the viral load in the lung. The high variability of
intranasal infection may even lead to better results in a less
variable animal model.
With the use of C57BL/6 mice, which are Mx-deficient
and hence incapable of an influenza-specific interferon type
I response, our study demonstrates that the inhibition of
influenza replication by dsDNAs in mouse lungs occurred
via an interferon-independent pathway. Moreover, in cell
culture, transfection of the dsDNAs used in this study with
Lipofectamine 2000 did not induce a type I interferon
response (data not shown). Our findings suggest that
dsDNAs exert their anti-influenza effects by inhibiting the
production of influenza virus RNA during infection. The
antisense strand of dsDNA PA50 is complementary to both
the influenza mRNA and cRNA. Our previous studies have
suggested that dsODN inhibits HIV-1 replication by
forming an RNA/DNA hybrid with the retroviral RNA and
hence inducing the RNase H activity of RT to degrade the
retroviral RNA [4–6]. Given that the influenza virus gen-
ome does not encode an RNase H, we propose that dsDNA
PA50 induces degradation of influenza viral RNA via dif-
ferent mechanisms, e.g. by activating cellular RNases H for
the degradation of the viral mRNA. We cannot exclude
other effects such as translational inhibition. Influenza
virus undergoes constant genetic changes. Novel thera-
peutics against an influenza virus pandemic are thus
urgently needed. This study is a proof-of-concept which
shows that dsDNAs may complement other classes of
nucleic-acid based inhibitors.
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